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Introduction 
The World Health Organisation (WHO) defines iron deficiency anaemia as Hb<130 g/L in 
men older than 15 years and <120 g/L in non-pregnant women older than 15 years. 
1 
 The 
commonest haematological abnormality in HNC patients at presentation is anaemia, usually 
from iron deficiency.
 2 
Reasons could include difficulties with nutrition due to dysphagia, 
poor diet, and life style (particularly high alcohol intake). With microvascular reconstruction 
following tumour ablation it is considered acceptable for haemoglobin levels to fall during 
surgery through blood loss and haemodilution, as reduced blood coagulability can help 
anastomosis success. Consequently, anaemia does occur intra-operatively and since peri-
operative blood transfusions (PBT) are avoided where possible, post-operative anaemia is 
common. This anaemia could contribute to poorer wound healing, fatigue, delayed recovery 
and worse health related quality of life. During follow-up around one fifth of patients report 
fatigue/tiredness.
 3 
 
A meta-analysis of 4984 patients from 28 articles, indicated preoperative anaemia as a 
potential risk factor for free flap failure, with postoperative transfusion associated with more 
medical complications.
 4 
Anaemia (< 12 g/dl) at different treatment times (pre and  
postoperative, before and during radiotherapy) was reported as an independent negative 
prognostic factor for local recurrence-free and overall survival in HNC patients.
 5
 Similar 
findings were reported by van de Pol et al.
 6
 Anaemia and BMI independently predicted 
overall survival for laryngeal SCC 
7
, whilst in oropharyngeal cancer, treated mainly by 
surgery, comorbidity and anaemia significantly influenced disease specific survival and had 
more impact on overall survival than p16 status.
 8
  
Peri-operative blood transfusion (PBT) rates in HNC free flap patients vary across units, for 
example from one quarter
 9 
to nearly half. 
10 
  One reason for this are differences in criteria for 
when to transfuse. Rossmiller 
11 
suggested a postoperative transfusion trigger of haematocrit 
< 25 percent which decreases blood transfusion rates without increasing flap-related 
complications. Clinical characteristics such as body mass index, tumour stage, preoperative 
haemoglobin level, and type of free-flap reconstruction have been identified as associates of 
PBT and can be used to inform risk stratification.
 9,12,13 
Occasionally a PBT is required for 
patients only having a neck dissection (ND).
 14
  
Every effort should be made to limit the amount of blood transfused as PBT carries risk. 
Patients receiving three or more units of blood after free tissue transfer for HNC were 
*Manuscript with title (excluding any author details including names and affiliations)
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 2 
reported as having significantly worse prognosis (survival, wound infection), 
15,16
 even after 
controlling for age, preoperative haemoglobin and albumin, cancer stage, and adverse 
pathologic features. The precise mechanism is unclear but might relate to an altered 
immunological response.
 17
 Fenner et al 
18
 reported that transfusion of >4 Units of blood did 
not appear to influence overall survival as the strongest predictors were age and ASA class. 
Other salient reasons to limit PBT relate to shortage of blood donations and expense. 
United Kingdom Multidisciplinary guidelines recommend that intravenous iron should be 
considered for anaemia in the urgent HNC patient, that preoperative blood transfusion should 
be avoided where possible, and when essential it should be completed 24–48 hours pre-
operatively. 
2 
There are also NICE guidelines for blood transfusion that are relevant. 
19, 20 
  
Though not specific to head and neck cancer and reconstructive microsurgery, the essence of 
these are, firstly that people with iron-deficiency anaemia who are having surgery are offered 
iron supplementation before and after surgery. Secondly, adults having surgery and expected 
to have moderate blood loss are offered tranexamic acid. Thirdly, people have their 
haemoglobin levels checked after each unit of red blood cells they receive, unless they are 
bleeding or are on a chronic transfusion programme. 
Hence there were two main study aims. Firstly, to audit haemoglobin levels peri-operatively, 
from pre-operative assessment to ward post-operative discharge, in patients having neck 
dissection or microvascular free tissue reconstruction for HNC. Secondly to audit which 
patients had blood transfusions, and the compliance against national transfusion guidelines.  
Patient and Methods 
Patients having neck dissection or microvascular free tissue reconstruction for HNC from 
October 2016 to September 2017 at Aintree Hospital Regional Maxillo-Facial Unit were 
included. There were no exclusion criteria. Cases were identified from theatre lists. 
Electronic patient records were used to access operation notes, blood prescription and results, 
discharge medication and first clinical outpatient review.  
The study was approved by the Clinical Audit Department at Aintree University Hospital. 
Fishers exact test was used to compare categorical data between patient groups. The Mann-
Whitney test (2 group comparison) or Kruskal-Wallis test (>2 group comparison) was used to 
compare numerical data between patient groups. Statistical significance was at the 5% level.  
Analyses were performed using SPSS version 25. 
 3 
Results 
There were 131 surgical patients, involving soft free-flaps for 50% (65), hard free-flaps for 
26% (34) and neck dissection only for 24% (32). For neck dissection patients, at a median 
(IQR) of 18 (12-28) days before surgery the median (IQR) pre-op Hb was 147 (136-157) g/L, 
n=28, range 118-185 g/L. Most (25/32) were admitted on the day of surgery, and at a median 
of 1 (0-2) days before discharge had a median (IQR) Hb of 131 (119-144) g/L, n=26, range 
104-163 g/L. Using the WHO definition of anaemia 4% (1/28) were anaemic pre-operatively 
and 42% (11/26) on discharge. No neck dissection patient received a blood transfusion and 
none were discharged on iron.  Group and save was first performed at a median (IQR) of 11 
(1-15) days and the second at 0 (0-1) days before surgery, n=25. The remainder of the results 
relates to free-flap surgery.    
 
 Median (IQR) age of the 99 free-flap surgery patients was 66 (57-72) years, 61 male and 38 
female. Three-quarters (74) had oral cancer, 8 oropharyngeal cancer, 5 ORN and 12 other. 
Staging was early (0-2) for 30, late (3-4) for 61, unknown for 8. Neck location was unilateral 
for 62, bilateral for 18 with vessel access for 19. Seven patients were in the AMG 319 trial.
 21 
 
 
At 3-4 weeks before surgery on average, one in five patients were anaemic (Table 1), with 3 
patients below 110g/L.  Twelve of 16 anaemic patients were aged 70 years or more; 41% 
(12/29) aged ≥70 were anaemic, 8% (2/26) aged 60-69, 7% (2/30) aged <60, P=0.001. On 
admission 47% of hard free-flap and 27% of soft free-flap patients were anaemic (P=0.10, 
Fishers exact test).  Two patients (1 hard, 1 soft) had Hb levels <100 g/L on admission and 
six more had an Hb of 100-109 g/L.  The first Group and Save was a median of 6 days before 
surgery and the second of 1 day before surgery. Haematinic deficiency checks were 
documented in 7% (7/99) of patients (3 hard, 4 soft) before surgery; one patient was put on 
folic acid, no action was taken for one, otherwise unknown.   
 
Hb levels fell by around 30 g/L on average from admission to during surgery (Table 1). Intra-
operative Hb fell below 80g/L for 14% (12/84), 80-89 g/L for 19% (16/84) and 90-99 g/L for 
19% (16/84). Almost all (98%) were anaemic. Four patients received tranexamic acid during 
surgery. There were surgical complications for 13% (13/99). Three-quarters (77%, 10/13) of 
patients with complications received one or more RBC transfusion, compared with 19% 
(16/86) without complications (P<0.001, Fishers exact test). One patient (hard free-flap) died 
 4 
in ITU. Other issues were haematoma evacuation (5), flap failure (4), flap salvage (1), 
bleeding/tracheostomy (1), blowout & haematoma evacuation (1).  
 
Post-surgery Hb changed little until discharge (Table 1). Discharge prescriptions (TTO’s) for 
iron were issued to 24% (8/33) hard and 23% (15/65) soft free-flap patients. Median (IQR) 
last Hb for patients discharged on iron was 93 (77-103) g/L, n=23 and was 103 (94-114) g/L, 
n=75 if not on iron, P=0.005 Mann-Whitney test. All 7 patients with last Hb <80 g/L were 
prescribed iron, 22% (2/9) if 80-89 g/L, 18% (6/33) if 90-99 g/L, 24% (5/21) if 100-109 g/L 
and 11% (3/28) if ≥110 g/L. Hb levels were reviewed at the next appointment for 18% 
(16/90), unknown for 8 followed elsewhere and reviews were mainly opportunistic. 
 
Forty-one red blood cell transfusions (61 units) were received by 26% (26/99), 35% (12/34) 
hard free-flap and 22% (14/65) soft free-flap. Most (61%, 26/41) transfusions were single 
unit, with 27% (11) transfused two units, 7% (3) three units and 2% (1) four units.  Four 
transfusions were before surgery, 29% (12) on the day of surgery, 32% (13) the day after, 
15% (6) two days after, 10% (4) 3-8 days after, and two after 19 and 31 days. Hb checks after 
each RBC unit were known for 39 transfusions (24 patients) and were done for 79% (31/39); 
33% (8/24) of patients had a transfusion episode without such a check, 2 with surgical 
complications. Twelve of the 39 transfusions were given during surgery with Hb checks for 
all. In addition to RBC transfusion, one (hard free-flap) patient received one unit of platelets 
and four units of fresh frozen plasma (FFP), and another (soft free-flap) received five units of 
FFP.  
 
Two patients were <100 g/L on admission and were transfused. One (soft ALT free-flap) was 
admitted 13 days before surgery (Hb 77 g/L) and was transfused two RBC units 9 days before 
surgery, one RBC unit 8 days before surgery and one unit the day after surgery.  The other 
(hard DCIA free-flap) patient was admitted one day before surgery (Hb 81g/) and received 
two RBC units on admission day and two more units on the day of surgery. One other patient 
was transfused before surgery, being admitted (Hb 120 g/L) for bleeding/tracheostomy; two 
RBC units were given 10 days before surgery with one further unit on the day of surgery.  
The patient transfused 31 days after surgery was given four RBC units three days after a 
second operation. The patient transfused 19 days after surgery had a lowest ward Hb of 71 
g/L and was transfused on the day of discharge.  Transfusions during days 3-8 after surgery 
were for patients already previously transfused since surgery.  
 5 
 
RBC transfusion was more strongly associated with lowest Hb during ITU than with 
admission or lowest intra-operative Hb (Table 2). Hb levels were more comparable by 
discharge (Table 3). The relation observed between lowest ITU, lowest ward and discharge 
Hb is shown in Table 4. Seven patients (7%) had last Hb levels <80 g/L and 4 of these had 
similar levels during their stay in ITU and all 7 during their ward stay. Two of these 7 
patients received one RBC unit one day after surgery and all 7 were prescribed iron on 
discharge. Another 9% (9) had a last Hb of 80-89 g/L.  
 
Admission Hb was significantly lower for females and for patients with late tumours (Table 
5).  None of the clinic-demographic variables measured were significantly associated with 
change in Hb from admission to the lowest recorded during surgery nor between admission 
and discharge.  Other than discharge Hb levels being significantly lower for hard free-flap 
surgery, no associations were observed. There were no statistically significant associations 
with being transfused, though it was observed that hard free-flap patients and later stage 
patients were transfused more often (Table 6). Females were more likely to be prescribed iron 
on discharge as were non-oral cancer patients. 
 
Discussion 
Anaemia and blood management in HNC patients is important since they relate to 
complications, survival and quality of life. In surgical settings anaemia can be managed by 
peri-operative blood transfusion (PBT), though not without risk. This retrospective case note 
review detailed Hb levels in patients having neck dissection and free flaps and comprises a 
consecutive contemporaneous sample but is limited in terms of being from a single 
institution. The findings have highlighted potential deficits in management and have allowed 
opportunities to reflect on how to improve. Neck dissection was included for comparative 
purposes and also because our current practice is to group and save and this carries cost 
implications.  
About one fifth of free-flap patients were anaemic at pre-operative assessment, and rates were 
highest in the elderly. Average time from pre-op assessment to operation was about three 
weeks, and as haemoglobin continues to fall in this period (on average 7-8 g/L) there is ample 
opportunity to administer IV iron (IVI). This strategy would comply with statement 1 of 
NICE guideline QS138. 
19
 
 6 
Around a 30g/L drop in Hb was seen for free-flap patients from admission to after operation. 
To reduce blood loss during resection we have now made it our practice to administer 
tranexamic acid (TXA) at the time of tumour ablation and so far TXA has been safe to use 
and has not comprised flap success. Although early findings are very positive this is the 
subject on an ongoing audit. TXA can significantly reduce blood loss and chances of colloid, 
blood, and crystalloid transfusion caused by HNC surgery.
 22 
However, in another study TXA 
did not reduce intraoperative blood loss or need for transfusions.
 23 
  The use of TXA 
complies with statement 2 of NICE guideline QS138. 
19 
  
Patients only having neck dissection (ND) usually present with higher Hb on admission and 
in this series no PBT was given. Discharge Hb levels were satisfactory and there was little 
indication for iron supplements. Very occasionally it will be necessary to give a PBT for 
patients having neck dissection.
 14 
 
One quarter of free-flap patients were transfused, mostly intra-operatively or in the first few 
days post-operatively. The local hospital recommendation is for patients only to have a blood 
transfusion in theatre or the high dependency unit if Hb falls below 90 g/L. Depending on the 
individual patient this might fall as low as 80 g/L and only then would patients definitely be 
given a transfusion. Most patients only had one unit of blood given and most had their 
haemoglobin levels checked after each unit of red blood cells. However, there is room for 
improvement regarding compliance with statement 3 of NICE guideline QS138.
19
  
The post-operative fall in Hb for free flap patients remained until discharge. There is 
evidence for correcting such anaemia, particularly for those having radiotherapy or 
chemotherapy, as anaemia has been shown as an independent significant prognostic factor in 
survival 
24
 and might relate to tumour cell oxygenation.  Levels <12 g/dl were associated with 
worse outcomes.
 25
 There is merit in giving IV iron during the post-operative in-patient stay. 
In our sample in spite of the frequency of post-operative anaemia only a quarter of patients 
were prescribed oral iron, due to concerns regarding its efficacy.  
In conclusion this cohort has highlighted the issue of blood loss and anaemia in patients 
having HNC tumour ablation associated with free tissue reconstruction. In respect of blood 
transfusion guidelines there were two areas that raised particular concern, namely the use of 
TXA and IVI. As post-operative anaemia is common IVI should be used where possible 
instead of blood transfusion and TXA should be given as part of resection management. 
Table 7 summarises a proposed schema for patients with head and neck cancer undergoing 
 7 
microvascular reconstruction. The patient benefit of these require further investigation but 
could lead to improved outcomes such as a reduction in complications, lower levels of fatigue 
and improved HRQOL. 
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Table 1. Haemoglobin levels before, during and after surgery. 
  
 Hard Free-flaps (N=34) Soft Free-flaps (N=65) 
 
Median (IQR) 
Days from surgery 
Median (IQR) Hb g/L 
WHO 
definition of 
anaemia* 
Median (IQR) Days 
from surgery 
Median (IQR) Hb g/L 
WHO 
definition of 
anaemia* 
Pre-op -22 (-31, -8), n=33 135 (128-145), n=28 21% (6/28) -27 (-39, -12), n=61 137 (129-147), n=57 18% (10/57) 
1st Group & Save** -6 (-14, -2), n=32   -6 (-23, -1), n=54   
2nd Group & Save -1 (-1, -1), n=32   -1 (-1, -1), n=60   
Admission 1 (-1, -1), n=34 127 (120-134), n=30 47% (14/30) 1 (-1, -1), n=64 130 (124-141), n=62 27% (17/62) 
Intra-op  93 (86-103), n=28 96% (27/28)  103 (86-113), n=56 98% (55/56) 
ITU lowest  89 (82-96), n=34 100% (34/34)  98 (86-108), n=65 100% (65/65) 
Ward lowest 6 (4-7), n=33 91 (86-96), n=33 100% (33/33) 3 (3-7), n=63 96 (85-103), n=65 100% (65/65) 
Last Hb 7 (7-13), n=33 95 (90-104), n=33 97% (32/33) 7 (4-13), n=65 103 (95-114), n=65 98% (64/65) 
Discharge 10 (8-14), n=33   9 (6-14), n=65   
 
*Males Hb<130 g/L, Females Hb<120 g/L 
 ** a further 12 (2 hard, 10 soft)  ‘had history’ while 1 (soft) had ‘none’ taken. 
  
Table(s)
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Table 2 Red Blood cell transfusion in relation to Haemoglobin levels at admission,  the lowest Hb 
recorded during surgery and the lowest recorded in ITU 
 
 
Hb g/L 
Hard 
free-flaps 
Soft free-
flaps 
All free-flaps 
Admission <70 - - - - 
 70-9 - 1/1 100% 1/1 
 80-9 1/1 - 100% 1/1 
 90-9 - - - - 
 100-109 2/2 3/4 83% 5/6 
 110-119 2/4 2/5 44% 4/9 
 120-129 4/13 6/19 31% 10/32 
 130+ 2/10 1/33 7% 3/43 
 Not known 1/4 1/3 29% 2/7 
Lowest during 
surgery 
<70 - 1/1 100% 1/1 
70-9 3/4 7/7 91% 10/11 
 80-9 2/6 4/10 38% 6/16 
 90-9 1/9 0/7 6% 1/16 
 100-109 2/6 1/15 14% 3/21 
 110-119 0/2 1/10 8% 1/12 
 120-129 - 0/6 0% 0/6 
 130+ 1/1 - 100% 1/1 
 Not known 3/6 0/9 20% 3/15 
Lowest in ITU <70 1/1 - 100% 1/1 
 70-9 6/6 3/5 82% 9/11 
 80-9 5/11 7/12 52% 12/23 
 90-9 0/11 4/19 13% 4/30 
 100-109 0/3 0/18 0% 0/21 
 110-119 0/2 0/8 0% 0/10 
 120-129 - 0/3 0% 0/3 
 130+ - - - - 
 Not known - - - - 
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Table 3: Haemoglobin levels by whether or not patient was transfused. 
 
Transfusion group 
Median (IQR) Hb g/L 
No-Transfusion 
group 
Median (IQR) Hb g/L 
P value* 
Pre-op 125 (117-135), n=19 138 (132-150), n=66 <0.001 
Admission 122 (109-127), n=24 133 (126-141), n=68 <0.001 
Intra-op 82 (75-90), n=22 104 (92-114), n=62 <0.001 
ITU lowest 83 (76-87), n=26 98 (92-108), n=73 <0.001 
Ward lowest 90 (82-96), n=25 96 (87-103), n=73 0.01 
Last Hb 98 (92-108), n=25 102 (92-113), n=73 0.45 
 
*Mann-Whitney test 
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Table 4. Lowest Haemoglobin level recorded  in ITU by last reading taken closest to discharge  
 
 
Last Hb (g/L) closest to discharge 
Total  70-9  80-9  90-9  100-109  110-119  120-129  130+ 
Lowest Hb (g/L) in ITU       
 <70 - - - 1 - - - 1 
 70-9 4 - 4 2 - - - 10 
 80-9 3 4 10 1 3 - 2 23 
 90-9 - 5 13 8 4 - - 30 
 100-109 - - 5 8 8 - - 21 
 110-119 - - 1 1 3 5 - 10 
 120-129 - - - - 2 1 - 3 
Total 7 9 33 21 20 6 2 98 
Lowest Hb (g/L) in ward       
 70-9 7 3 1 1 1 - - 13 
 80-9 - 6 11 2 2 - - 21 
 90-9 - - 21 9 6 - 2 38 
 100-109 - - - 9 6 1 - 16 
 110-119 - - - - 5 3 - 8 
 120-129 - - - - - 2 - 2 
Total 7 9 33 21 20 6 2 98 
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Table 5. Haemoglobin levels in relation to patient and clinical characteristics 
  
Median (IQR) 
Admission Hb (g/L) P 
value* 
Median (IQR) 
Decrease in Hb 
(g/L) from 
admission to 
Lowest during 
surgery 
P 
value* 
Median (IQR) 
Decrease in Hb (g/L) 
from admission to 
discharge 
P 
value* 
Median (IQR)  
Last Hb (g/L) P 
value* 
All patients  129 (122-140), n=92 30 (20-40), n=78 29 (18-38), n=91 100 (92-111), n=98 
Surgical 
group 
Hard Free-flap 127 (120-134), n=30 
0.10 
32 (25-40), n=24 
0.36 
32 (23-37), n=29 
0.41 
95 (90-104), n=33 
0.005 
Soft Free-flap 130 (124-141), n=62 30 (17-42), n=54 27 (17-38), n=62 103 (95-114), n=65 
Gender Male 134 (125-141), n=55 
0.005 
32 (24-43), n=46 
0.07 
30 (22-39), n=54 
0.23 
102 (93-113), n=60 
0.30 
 Female 126 (120-131), n=37 24 (17-39), n=32 27 (12-36), n=37 98 (91-109), n=38 
Age <60 127 (121-140), n=34 
0.25 
30 (18-37), n=30 0.56 27 (14-40), n=34 0.11 98 (91-113), n=36  
 60-69 134 (126-140), n=31 31 (24-43), n=24  34 (24-39), n=31  102 (91-110), n=31 0.87 
 ≥70 128 (120-140), n=27 28 (17-43), n=24  28 (18-33), n=26  102 (92-113), n=31  
Diagnosis Oral 129 (123-140), n=68 
0.55 
oral Vs 
rest 
30 (19-39), n=58 
0.37 
oral Vs 
rest 
29 (19-38), n=67 
0.90 
oral Vs 
rest 
102 (91-112), n=73 
0.81 
oral Vs 
rest 
 Oropharyngeal 130 (na), n=8 34 (na), n=7 30 (na), n=8 105 (na), n=8 
 ORN 129 (na), n=5 34 (na), n=5 31 (na), n=5 97 (na), n=5 
 Other 124 (120-140), n=11 30 (na), n=8 28 (22-37), n=11 95 (80-113), n=12 
Stage Early 133 (126-143), n=29 0.05 
excl NK 
31 (22-44), n=23 0.56 
excl NK 
29 (20-38), n=29 0.81 
excl NK 
105 (95-115), n=30 0.14 
excl NK  Late 127 (121-139), n=55 30 (18-40), n=47 29 (21-38), n=54 99 (90-110), n=60 
 NK 122 (na), n=8  29 (na), n=8  24 (na), n=8  98 (na), n=8  
Neck Unilateral 129 (124-140), n=58 
0.60 
28 (18-40), n=48 0.33 32 (22-38), n=57 0.58 100  (91-113), n=61  
 Bilateral 129 (123-141), n=17 36 (21-49), n=15  26 (12-39), n=17  103 (98-111), n=18 0.22 
 Vessel access 127 (119-137), n=17 33 (22-41), n=15  28 (16-39), n=17  95 (91-106), n=19  
 
*Mann-Whitney (2 group comparison) or Kruskall-Wallis (>2 group comparison) test 
Also Note: (na) refers to IQR not being given as there was <10 cases 
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Table 6 Red Blood Cell transfusion and prescription of iron on discharge, in relation to patient and 
clinical characteristics 
  % (n) with RBC 
transfusion P value* 
% (n) prescribed iron on discharge 
P value* 
All patients  26% (26/99) 23% (23/98) 
Surgical group Hard Free-flap 35% (12/34) 
0.16 
24% (8/33) 
>0.99 
 Soft Free-flap 22% (14/65) 23% (15/65) 
Gender Male 23% (14/61) 
0.36 
17% (10/60) 
0.05 
 Female 32% (12/38) 34% (13/38) 
Age <60 25% (9/36) 
0.96 
19% (7/36) 
0.80  60-69 26% (8/31) 26% (8/31) 
 ≥70 28% (9/32) 26% (8/31) 
Diagnosis Oral 23% (17/74) 
0.29 Oral 
Vs Rest 
18% (13/73) 
0.03 Oral 
Vs rest 
 Oropharyngeal 50% (4/8) 38% (3/8) 
 ORN 60% (3/5) 20% (1/5) 
 Other 17% (2/12) 50% (6/12) 
Stage Early 17% (5/30) 0.30 excl 
NK 
13% (4/30) 0.30 excl 
NK  Late 28% (17/61) 28% (17/60) 
 NK 50% (4/8)  25% (2/8)  
Neck Unilateral 24% (15/62) 
0.76 
23% (14/61) 
0.59  Bilateral 28% (5/18) 17% (3/18) 
 Vessel access 32% (6/19) 32% (6/19) 
 
*Fishers exact test 
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Table 7; Proposed schema for patients with head and neck cancer undergoing microvascular 
reconstruction 
 
 
Pre-operative  Early pre-operative bloods to identify patients with iron 
deficiency anaemia. Ideally immediately following the 
consultation at which treatment planned agreed. 
Haemocue can help rapid identification of anaemia. 
 If Hb less than 120 consider administration of IV iron as 
soon as possible before planned operation date 
 Re-check Hb two weeks later, assess need for second 
treatment, though if close to time of surgery it will be 
likely that there will be a need for peri-operative 
transfusion or IV iron post-operatively 
Intra-operative • Optimal surgical techniques to avoid blood loss 
• Hypotensive anaesthesia 
• Hourly assessment of blood loss and Hb checks  
• Administration of 1 gram tranexamic acid at start of 
resection 
• Consider cell salvage 
 Use of single unit transfusions unless massive unexpected 
blood loss 
Post-operative  The use of blood transfusion will depend on unit 
protocols and individual patient considerations 
 If Hb less than 120 at day two / three consider IV iron  
 Avoid use of oral oral iron – low efficacy and side-effects 
 Check Hb prior to discharge and review in first 
consultation post-discharge. If less that 120 consider 
repeat IV iron if two weeks following the most recent 
infusion 
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